1. A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I. (5th June 2019) Authors: Dodick, DW; Lipton, RB; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Trugman, JM; Szegedi, A; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I. (June 2019) Authors: Dodick, DW; Lipton, RB; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Trugman, JM; Szegedi, A; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II. (5th June 2019) Authors: Lipton, RB; Dodick, DW; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Szegedi, A; Trugman, JM; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II. (June 2019) Authors: Lipton, RB; Dodick, DW; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Szegedi, A; Trugman, JM; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P.015 Monthly migraine days, acute medication use-days, and migraine-specific quality of life in responders to atogepant: a post hoc analysis. (June 2022) Authors: Dodick, DW; Lipton, RB; Nahas, SJ; Pozo-Rosich, P; McAllister, P; Mechtler, LL; Leroux, E; Ma, J; Dabruzzo, B; Dufek, M; Severt, L; Finnegan, M; Trugman, J Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P.017 Optimization of acute treatment and headache-related impact following eptinezumab initiated during a migraine attack: post hoc analysis of the RELIEF study. (June 2022) Authors: Buse, DC; Lipton, RB; Ettrup, A; Josiassen, MK; Lindsten, A; Cady, R; Omeragic, A; Duong, A Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P.019 Interictal burden of migraine: correlations with other measures of migraine burden and effects of galcanezumab migraine-preventive treatment. (June 2022) Authors: Sandoe, CH; Lipton, RB; Buse, DC; Ford, JH; Hand, AL; Jedynak, JP; Port, MD; Detke, HC Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P.029 Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. (November 2021) Authors: Lipton, RB; Pozo-Rosich, P; Blumenfeld, AM; Dodick, DW; McAllister, P; Li, Y; Lu, K; Dabruzzo, B; Davidovic, G; Miceli, R; Severt, L; Finnegan, M; Trugman, JM Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗